The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
Johann Sebastian De Bono
Employment or Leadership Position - The Institute of Cancer Research
Lida A. Mina
No relevant relationships to disclose
Michael Gonzalez
No relevant relationships to disclose
Nicola J. Curtin
Consultant or Advisory Role - Biomarin
Research Funding - Biomarin
Evelyn Wang
Employment or Leadership Position - Biomarin
Stock Ownership - Biomarin
Joshua W. Henshaw
Employment or Leadership Position - Biomarin
Stock Ownership - Biomarin (B)
Manpreet Chadha
No relevant relationships to disclose
Jasgit C. Sachdev
No relevant relationships to disclose
Daniela Matei
No relevant relationships to disclose
Gayle S. Jameson
No relevant relationships to disclose
Michael Ong
No relevant relationships to disclose
Bristi Basu
No relevant relationships to disclose
Zev A. Wainberg
No relevant relationships to disclose
Lauren Averett Byers
No relevant relationships to disclose
Rashmi Chugh
No relevant relationships to disclose
Andrew Dorr
Consultant or Advisory Role - Biomarin
Other Remuneration - Biomarin
Stanley B. Kaye
Consultant or Advisory Role - Biomarin
Honoraria - Biomarin
Ramesh K. Ramanathan
Research Funding - Biomarin